Bruker Introduces the Ingenious Novel ‘Triceratops’ SPR #64 Surface Plasmon Resonance System for Drug Discovery at SLAS2024
- The 'Triceratops' SPR #64 system offers increased throughput and data quality, making it a valuable tool for drug discovery.
- The system combines highest sensitivity detection with a novel microfluidics concept, facilitating the simultaneous reading of 64 sensor spots.
- Automation features and integrated software make it a milestone in convenient SPR-based biopharma research.
- None.
Enables the Simultaneous Measurement of 64 Molecular Interactions
‘Triceratops’ SPR #64: the all new, high-throughput multiplexing Surface Plasmon Resonance (SPR) system (Photo: Business Wire)
The ‘Triceratops’ SPR #64 system combines highest sensitivity detection with a novel microfluidics concept, which via the perpendicular rotation of the 8-channel flow cell, now facilitates the simultaneous reading of 64 sensor spots. This ingenious design extends SPR capabilities beyond previous limits, accelerating screening, kinetics, epitope characterization, condition scouting, concentration analysis, and thermodynamics. With the ‘Triceratops’ SPR #64, Bruker is now offering drug discovery customers the highest throughput in the industry with uncompromising data quality.
Immediate SPR #64 access and visual controls are facilitated through a built-in touchscreen. Automation features, including integration of any external robot, as well as the direct control via its API, mark a new milestone in convenient SPR-based biopharma research. The SPR #64 software integrates high performance, flexibility, and ease of use throughout every stage, from acquisition to final reports. Each module is intuitively designed, offering guidance for key applications such as SPR affinity and kinetics determination, thermodynamics, and epitope characterization.
David Myszka, Ph.D., Director at Biosensor Tools LLC in
Dr. Martin Kleinschmidt, Group Leader Bioanalytics in the Department of Drug Design and Target Validation at the Fraunhofer Institute for Cell Therapy and Immunology in
Dr. Meike Hamester, VP Label-Free Biopharma Technologies at Bruker Daltonics, concluded: “The ‘Triceratops’ SPR #64, our exciting new high-end SPR system for drug discovery, is nicely complemented by Bruker’s SPR-24 Pro and SPR-32 Pro systems to meet any throughput requirement.”
About Bruker Corporation (Nasdaq: BRKR)
Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity and customer success in life science molecular and cell biology research, in applied and pharma applications, in microscopy and nanoanalysis, as well as in industrial applications. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit: www.bruker.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240205314598/en/
Investor Contact:
Justin Ward
Sr. Director, Investor Relations & Corporate Development
Bruker Corporation
T: +1 (978) 313-5800
E: Investor.Relations@bruker.com
Media Contact:
Petra Scheffer
Marketing Communications
Bruker Daltonics
T: +49 (421) 2205-2843
E: petra.scheffer@bruker.com
Source: Bruker Corporation
FAQ
What is the new SPR instrument introduced by Bruker Corporation at the SLAS2024 International Conference and Exhibition?
What is the ticker symbol for Bruker Corporation?
How many sensor spots does the 'Triceratops' SPR #64 system facilitate the simultaneous reading of?